Can practices still prescribe compounded semaglutide in 2026?

It depends on the compounding pathway. The FDA ended the semaglutide shortage in February 2025, which eliminated the shortage exception that 503B outsourcing facilities used to compound copies of brand-name semaglutide. However, 503A pharmacies may still have pathways to compound semaglutide under certain conditions, including the essentially a copy provision with clinical differentiation. The regulatory environment continues to evolve, so practices should work with their pharmacy partners and legal counsel to understand current options.

What happened when the FDA ended the semaglutide shortage?

When the FDA determined that the semaglutide shortage had resolved in February 2025, it triggered a wind-down period for 503B outsourcing facilities that had been compounding semaglutide under the shortage exception. These facilities were given 60 days to stop distributing compounded semaglutide. 503A pharmacies were subject to different enforcement timelines. The practical effect was a significant reduction in the availability of compounded semaglutide from 503B sources.

Is compounded tirzepatide still available?

Tirzepatide (the active ingredient in Mounjaro and Zepbound) had a separate regulatory timeline from semaglutide. Check the FDA's current drug shortage database for the latest status. If tirzepatide remains on the shortage list, compounding pharmacies may continue to compound it under the shortage exception. When the shortage resolves, the same wind-down process that applied to semaglutide would apply to tirzepatide.

What is the difference between brand-name and compounded GLP-1 medications?

Brand-name GLP-1 medications like Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) are manufactured by pharmaceutical companies at standardized doses with FDA approval. Compounded versions are prepared by compounding pharmacies and can offer custom dosing, different formulations, and often lower patient cost. Compounded medications are not FDA-approved but are legally compounded under specific regulatory frameworks.

How should practices adapt their GLP-1 programs to the new regulations?

Practices should build flexible programs that do not depend on a single compounding pathway. This means establishing relationships with multiple pharmacy partners, maintaining the ability to prescribe brand-name GLP-1 medications, diversifying into adjacent programs like peptide therapy and hormone optimization, and using platforms that can route prescriptions to the best available source as regulations evolve.

What are the legal risks of prescribing compounded GLP-1 medications?

The primary risk is prescribing compounded medications outside of the legally permitted pathways. Practices should ensure their pharmacy partners are operating within their regulatory authority (503A or 503B), that prescriptions meet all requirements for the applicable pathway, and that patient informed consent clearly explains the compounded nature of the medication. Working with a healthcare attorney familiar with compounding law is advisable.

Will GLP-1 compounding rules change again?

Almost certainly. The compounding industry is subject to ongoing FDA rulemaking, court decisions, and legislative activity. The Alliance for Pharmacy Compounding and individual compounding pharmacies have challenged FDA enforcement actions in court. Congressional interest in compounding access remains high. Practices should build programs that can adapt to regulatory changes rather than depending on any single regulatory interpretation.

GLP-1 Compounding Regulations 2026: What Changed for Medical Practices

The GLP-1 compounding market changed dramatically in 2025, and practices running medical weight loss programs need to understand what happened, where things stand now, and how to build programs that can adapt as regulations continue to evolve.

This guide covers the key regulatory changes, what they mean for your practice, and practical strategies for running a sustainable GLP-1 weight loss program in 2026.

Timeline: What Happened

The Shortage Era (2022-2025)

The GLP-1 story starts with unprecedented patient demand. As semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) gained mainstream attention for weight loss, demand far exceeded supply from the brand manufacturers Novo Nordisk and Eli Lilly.

The FDA added semaglutide to the drug shortage list, which triggered an important legal exception: under Section 503B of the Federal Food, Drug, and Cosmetic Act, outsourcing facilities can compound copies of commercially available drugs during a declared shortage.

This opened the door for compounding pharmacies to produce semaglutide and tirzepatide, creating a secondary market of compounded GLP-1 medications. Thousands of medical practices built weight loss programs around compounded semaglutide, often at significantly lower patient cost than brand-name alternatives.

February 2025: The Shortage Ends

In February 2025, the FDA announced that the semaglutide shortage had resolved. This was the pivotal moment for compounding practices because the shortage resolution removed the legal basis for 503B facilities to compound copies of brand-name semaglutide.

The FDA established a wind-down period:

503B outsourcing facilities received a 60-day wind-down period to stop distributing compounded semaglutide
503A pharmacies were subject to separate enforcement considerations, with the FDA acknowledging that 503A compounding operates under different legal authority

Legal Challenges

The end of the shortage did not go unchallenged. Compounding pharmacies and industry groups filed legal challenges arguing that the FDA’s shortage resolution was premature, that patient access would be harmed, and that specific compounding pathways remained legally available even outside the shortage exception.

Several court actions resulted in temporary restraining orders and preliminary injunctions that delayed or modified FDA enforcement in specific cases. The legal environment has continued to evolve through 2025 and into 2026.

Current Status (2026)

As of mid-2026, the situation is:

503B compounding of semaglutide copies under the shortage exception has largely ended, though some legal challenges continue in specific jurisdictions
503A pharmacy compounding operates under different authority, and some 503A pharmacies continue to compound semaglutide under provisions that do not rely on the shortage exception
Tirzepatide has followed its own regulatory timeline, with its shortage status tracked separately by the FDA
Brand-name prescribing through Novo Nordisk and Eli Lilly remains available, though patient cost is significantly higher than compounded alternatives were
Congressional attention to compounding access remains active, with proposals to clarify or expand compounding authority

Understanding the Regulatory Pathways

503A: Patient-Specific Compounding

503A pharmacies compound medications based on individual patient-specific prescriptions. Their authority comes from Section 503A of the FD&C Act and is primarily regulated by state pharmacy boards.

Key points for GLP-1 compounding:

Not dependent on shortage declarations. 503A compounding authority is not tied to whether a drug is in shortage. The legal framework is different from 503B.
“Essentially a copy” provisions. 503A pharmacies generally cannot compound drugs that are “essentially a copy” of a commercially available product unless they meet specific conditions, including clinical differentiation documented by the prescriber.
State-level variation. State pharmacy boards interpret and enforce compounding regulations differently. What is permitted in one state may not be in another.
Prescriber relationship required. 503A compounding requires a valid patient-specific prescription from a licensed prescriber with a documented patient relationship.

503B: Outsourcing Facilities

503B outsourcing facilities are FDA-registered and can compound in larger batches, but their ability to compound copies of commercially available drugs is limited:

Shortage exception removed for semaglutide. Once the shortage ended, 503B facilities lost the legal basis to compound copies of brand-name semaglutide under this specific provision.
Other pathways may exist. 503B facilities can compound drugs that appear on the FDA’s bulk drug substances list and are not essentially a copy of a commercially available drug. Whether specific GLP-1 formulations qualify depends on the formulation details and FDA interpretation.
FDA inspection and oversight. 503B facilities face more rigorous federal oversight than 503A pharmacies, including FDA inspections and cGMP requirements.

Brand-Name Prescribing

Prescribing brand-name Ozempic, Wegovy, Mounjaro, or Zepbound remains straightforward:

No compounding regulatory complexity. You are prescribing an FDA-approved medication through standard pharmacy channels.
Higher patient cost. Without insurance coverage, brand-name GLP-1 medications cost significantly more than compounded alternatives. Manufacturer savings programs exist but have eligibility requirements.
Supply stability. Brand-name supply has largely stabilized since the acute shortage period, though availability can vary by dosage strength and region.

How Practices Should Adapt

The practices that are thriving in 2026 are the ones that built flexible programs rather than depending on a single compounding pathway.

Strategy 1: Multi-Pharmacy Relationships

Do not rely on a single pharmacy partner. Build relationships with multiple pharmacies across different regulatory pathways:

A 503A pharmacy that has a defensible pathway for GLP-1 compounding
A 503B facility for medications where they have clear authority (peptides, hormones, non-GLP-1 compounds)
Brand-name prescribing capability as a fallback or premium option

This gives you supply chain resilience regardless of how the regulatory environment evolves. See our guide to choosing pharmacy partners for a detailed evaluation framework.

Strategy 2: Diversify Beyond GLP-1

The GLP-1 compounding restrictions reinforced an important lesson: programs dependent on a single therapy type are vulnerable. Practices that diversified into adjacent programs absorbed the GLP-1 changes more easily.

Peptide therapy is the most natural complement to GLP-1 weight loss. With the expected FDA peptide reclassification, peptide therapy programs are poised for growth. The patient demographic overlaps significantly with GLP-1 patients.

Testosterone replacement therapy (TRT) and hormone replacement therapy (HRT) serve different patient populations but share the same operational infrastructure: patient intake, clinical review, compounding pharmacy fulfillment, and automated follow-up.

Running multiple programs from a single platform means the infrastructure investment for your first program pays dividends across every additional program you add.

Strategy 3: Build on a Flexible Platform

Your technology platform should make it easy to adapt as regulations change:

Multi-pharmacy routing so you can switch pharmacy sources without changing your workflow
Program-agnostic infrastructure that supports GLP-1, peptides, TRT, and HRT from the same system
Intake and prescribing flexibility so adding a new therapy does not require building new infrastructure
Pharmacy integration that handles the routing and fulfillment complexity for you

Practices that built custom workflows tied to a single pharmacy or therapy type are the ones scrambling to adapt. Practices on flexible platforms simply adjust their pharmacy routing and continue operating.

Strategy 4: Stay Informed

The regulatory environment is not static. Stay current on:

FDA enforcement actions and guidance related to compounding
Court decisions that may expand or restrict compounding authority
State pharmacy board updates for states where you practice or have patients
Industry group communications from organizations like the Alliance for Pharmacy Compounding and relevant medical societies

Your pharmacy partners should be a source of regulatory intelligence. Good pharmacy partners proactively communicate about changes that affect your prescribing.

What This Means for Your Weight Loss Program

If you are running a GLP-1 weight loss program or considering starting one, here is the practical takeaway:

GLP-1 weight loss programs are still viable and profitable. The regulatory changes affected the compounding supply chain, not the clinical viability or patient demand for medical weight loss. Patients still want medically supervised weight loss programs. The question is how you source the medication and structure the program.

Build for flexibility. Design your program to work across multiple GLP-1 sources: compounded (where legally available), brand-name, and potentially new entrants as the market evolves.

Complement with adjacent programs. Peptide therapy, TRT, and HRT share infrastructure and patient demographics with GLP-1 weight loss. Offering multiple programs reduces your dependence on any single therapy.

Use technology to manage complexity. Multi-pharmacy routing, automated patient follow-up, and integrated prescribing workflows make it possible to run a flexible program without proportionally increasing administrative overhead.

How Karpa Health Helps

Karpa Health is built for exactly this kind of regulatory flexibility. The platform supports:

GLP-1 weight loss programs with multi-pharmacy routing to integrated pharmacy partners
Peptide therapy programs ready for the expected Category 1 reclassification
TRT and HRT programs from the same platform
AI-powered clinical review that reduces physician time per patient regardless of the therapy type
Automated patient follow-up that keeps patients on protocol across all programs

The platform adapts as regulations change. When a pharmacy pathway opens or closes, you adjust your routing without rebuilding your program infrastructure.

Book a demo to see how Karpa Health supports flexible GLP-1 and multi-program practices.